Researchers from the North Bristol NHS Trust, Academic Respiratory Unit in Bristol, UK, recently uploaded study results to the medRxiv preprint server. The study team sought to identify if the corticosteroid dexamethasone, proven to reduce COVID-19 mortality in certain hospitalized acute COVID-19 pneumonia scenarios thanks to the RECOVERY trial, could help reduce symptoms associated with long-COVID.
The RECOVERY trial led to a material change in how acute COVD-19 was managed, and according to the study authors, saved approximately 1 million lives worldwide.
Importantly, however, steroids have a downside, even if administered on a short-term basis. In the case of the RECOVERY trial, the benefits were constrained to patients requiring oxygen or already on a ventilator as compared to patients less severely affected—the latter could actually be harmed by the regimen.
A Real Problem
Long-COVID, also known as post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), or chronic COVID syndrome (CSS) is characterized by long-term sequelae appearing or persisting well after the preliminary infection period associated with SARS-CoV-2. This condition may impact every...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).